P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the ...
Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007; 22: [Epub ahead of print]. MEDLINE 8. Wolanskyj AP, Schwager SM ...
With phase 3 trial win, PharmaEssentia plots label expansion for rare blood cancer treatment Besremi
PharmaEssentia is looking to expand the reach of its FDA-approved rare blood cancer treatment Besremi to another rare blood ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback